How confidence intervals become confusion intervals
 James McCormack^{1},
 Ben Vandermeer^{2} and
 G Michael Allan^{3}Email author
DOI: 10.1186/1471228813134
© McCormack et al.; licensee BioMed Central Ltd. 2013
Received: 8 August 2013
Accepted: 29 October 2013
Published: 31 October 2013
Abstract
Background
Controversies are common in medicine. Some arise when the conclusions of research publications directly contradict each other, creating uncertainty for frontline clinicians.
Discussion
In this paper, we review how researchers can look at very similar data yet have completely different conclusions based purely on an overreliance of statistical significance and an unclear understanding of confidence intervals. The dogmatic adherence to statistical significant thresholds can lead authors to write dichotomized absolute conclusions while ignoring the broader interpretations of very consistent findings. We describe three examples of controversy around the potential benefit of a medication, a comparison between new medications, and a medication with a potential harm. The examples include the highest levels of evidence, both metaanalyses and randomized controlled trials. We will show how in each case the confidence intervals and point estimates were very similar. The only identifiable differences to account for the contrasting conclusions arise from the serendipitous finding of confidence intervals that either marginally cross or just fail to cross the line of statistical significance.
Summary
These opposing conclusions are false disagreements that create unnecessary clinical uncertainty. We provide helpful recommendations in approaching conflicting conclusions when they are associated with remarkably similar results.
Keywords
Confidence intervals Evidence based medicine Statistical analysis Statistical significanceBackground
Most published reports of clinical studies begin with an abstract – likely the first and perhaps only thing many clinicians, the media and patients will read. Within that abstract, authors/investigators typically provide a brief summary of the results and a 1–2 sentence conclusion. At times, the conclusion of one study will be different, even diametrically opposed, to another despite the authors looking at similar data. In these cases, readers may assume that these individual authors somehow found dramatically different results. While these reported differences may be true some of the time, radically diverse conclusions and ensuing controversies may simply be due to tiny differences in confidence intervals combined with an overreliance and misunderstanding of a “statistically significant difference.” Unfortunately, this misunderstanding can lead to therapeutic uncertainty for frontline clinicians when in fact the overall data on a particular issue is remarkably consistent.
A key concept of science is the formulation of hypotheses and the testing these hypotheses by observing a set of data. Typically in medicine one starts with an idea that a therapy will have an effect. A statistical test assumes that an intervention has no effect and this is called the null hypothesis. A statistical evaluation simply provides information as to how likely that the finding of a particular difference could be due to chance and if there really was no difference between the treatment groups.
We can NEVER prove a null hypothesis, meaning the intervention has absolutely no effect. However, we design clinical studies with the hope they will provide information to help decide if we should reject or fail to reject the null hypothesis. Rejecting the null hypothesis is often interpreted to mean the intervention has an effect; failing to reject the null hypothesis is interpreted to mean the intervention does not have an effect. These simplistic interpretations ignore important factors such as clinical importance, precision of the estimate, and statistical power.
A welldesigned randomized controlled trial (RCT) is usually the least biased way to evaluate the difference between different therapeutic interventions. Unless an RCT has studied the entire population of interest, the observed difference or ratio that is found is called a point estimate because only a small sample of the entire population has been evaluated. A point estimate is typically presented with a 95% (or less commonly 99%) confidence interval (CI). A CI, while it has other interpretations, can be thought of as a range of numeric outcomes that we are reasonably confident includes the actual result.
The choice of a specific CI typically comes from the convention of a pvalue of 0.05 representing a statistical significance. This threshold has been discussed as being arbitrary but has also been suggested to represent a reasonable threshold [1]. Any statistical threshold can be debated because a threshold depends on how comfortable one is that the results of a particular study may be due to chance. However, what cannot be debated is that this threshold was never developed to allow researchers or clinicians to make dichotomous conclusions that, if a pvalue is greater than 0.05, the intervention has no effect and, if a pvalue is less than 0.05, the intervention has an effect. When using CIs to assess statistical significance, the “no effect” cutoff occurs when the CI touches the line of 1 for relative risks or odds ratios, and 0 for absolute risks and weighted mean differences.
 1)
In patients without a history of cardiovascular disease, do statins reduce mortality?
 2)
In patients with atrial fibrillation, when compared to warfarin, is apixaban more effective than dabigatran at reducing mortality?
 3)
In patients who smoke, does the use of varenicline increase the risk of serious cardiovascular adverse events?
Statins
Example 1. In patients without a history of cardiovascular disease, do statins reduce mortality?
Statins are widely used in patients with and without established cardiovascular disease. An important clinically relevant question is: do statins have an effect on overall mortality in patients who have not experienced a cardiovascular event? Because of the relatively low baseline 5year risk of mortality in this population (roughly 5% over 5 years), no single study has been powered sufficiently to provide a clear answer. For that reason, at least five different metaanalyses examining this question have been published [2–6].
The authors of these metaanalyses concluded the following:

Studer et al.: “statins and n3 fatty acids are the most favorable lipidlowering interventions with reduced risks of overall and cardiac mortality.” [2]

Thavendiranathan et al.: “statin therapy decreases the incidence of major coronary and cerebrovascular events and revascularizations but not coronary heart disease or overall mortality.” [3]

Mills et al.: “We examined the impact of statin therapy on major events and found an important role in preventing allcause mortality” [4] although this quote was not found in the abstract but rather the first line of the discussion.

Brugts et al.: “statin use was associated with significantly improved survival.” [5]

Ray et al.: “this literaturebased metaanalysis did not find evidence for the benefit of statin therapy on allcause mortality.” [6]
Novel oral anticoagulants
Example 2. In patients with atrial fibrillation, when compared to warfarin, is apixaban more effective than dabigatran at reducing mortality?
A new class of oral anticoagulants (OACs) has recently been released on the market. An important clinical question is which one of these new agents is the most effective; does either agent reduce mortality more than the “goldstandard” warfarin? Two separate studies compare two of the new OACs and warfarin [7, 8].
Connolly et al. state “The mortality rate was 4.13% per year in the warfarin group, as compared with 3.75% per year with 110 mg of dabigatran (P = 0.13) and 3.64% per year with 150 mg of dabigatran (P = 0.051)” [7]. The authors do not make any specific conclusions on mortality differences between warfarin and dabigatran.
In contrast, Granger et al. (ARISTOTLE) concluded that “apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality” [8]. Interestingly, the press stated: “ARISTOTLE: A major win for apixaban in AF”, “the most positive yet” and “first of the three new oral anticoagulants to show a clearly significant reduction in allcause mortality.” [9]
The Granger paper [8] illustrates the importance that authors attach whether or not results cross the magical line of 1.0 and statistically significance. In Table Two of the article, the authors present 10 outcome results –for 9 they include the upper limit of the CIs with numbers to two decimal points. Yet for the mortality data, they show the upper limit number to 3 decimal points (0.800.998) [8]. Interestingly, for the mortality CIs in the abstract and the body of the paper, this 0.998 result was rounded down to 0.99 rather than the more correct rounding up to 1.00.
Varenicline
Example 3. In patients who smoke, does the use of varenicline increase the risk of serious cardiovascular adverse events?
Varenicline is a new smoking cessation medication that is widely used. As with most new medications, the longterm or rare side effects are unknown. For that reason investigators have conducted metaanalyses of many small trials to try to identify any previously unknown adverse effects. Two metaanalyses have examined a possible risk of serious cardiovascular events with varenicline [10, 11].
Singh et al. reported that “Our metaanalysis raises safety concerns about the potential for an increased risk of serious adverse cardiovascular events associated with the use of varenicline.” [10]
In contrast a later metaanalysis by Prochaska et al. reported that varenicline used for smoking cessation produced “no significant increase in cardiovascular serious adverse events associated with varenicline use” [11]. These authors go on to state “The consequence of inflated risk estimates, such as those from Singh and colleagues’ metaanalysis concerning the effect of varenicline on serious adverse events related to cardiovascular disease, can be unnecessary public alarm and real harm, since patients may discontinue their drug treatment out of fear of adverse effects and clinicians may recommend cessation treatments of reduced efficacy or discourage use of the drug treatment altogether.” [11]
Pragmatic interpretation of the included studies
Based on the evidence presented, we believe the following represents a reasonable and pragmatic interpretation of the results and how a clinician might use the information.
Statins’ effect on overall mortality in primary prevention
If you were a betting person, you should bet that statins likely reduce mortality in primary prevention. The average point estimate in these metaanalyses was around 0.90 or a 10% relative reduction [2–6]. The relative reduction may vary from 0 to 20% but 10% is a reasonable approximation [2–6]. The baseline risk of mortality was approximately 5% [2–6], so using the 10% risk reduction gives a 0.5% absolute reduction. Therefore, we need to treat 200 primary prevention patients for one extra person to avoid death over 5 years. Conversely, 199 will not get a benefit in changing their risk of mortality. The CI also suggests the absolute reduction in risk could be as high as 1% or as little as 0%. Given the results we can confidently say it is very unlikely that statins increase mortality. Bottomline, statins seem to have roughly a 1 in 200 effect on overall mortality in primary prevention.
Novel anticoagulants effect on overall mortality in atrial fibrillation
The evidence does not suggest any differences between apixaban and dabigatran and their effect on mortality compared to warfarin. As with the statins, dabigatran and apixaban likely do reduce mortality, approximately 10% with a CI of 0% to 20% [7, 8]. The baseline death rate on warfarin was roughly 4% per year [7, 8] so the reduction in risk would be 0.4% although it could be as high as 0.8% or low as 0%. Therefore, we need to treat 250 atrial fibrillation patients with apixaban or dabigatran instead of warfarin for one extra person to avoid death over 1 year. Conversely, 249 will not get a benefit in changing their risk of mortality. (Note: baseline death rates may vary considerably based on a specific CHADS score but we are using the average from the clinical trials included [7, 8].) Based on the evidence, it is very unlikely that dabigatran or apixaban increase mortality compared to warfarin. Bottomline, compared to warfarin, dabigatran and apixaban seem to have a 1 in 250 benefit on overall mortality in one year in atrial fibrillation patients.
Varenicline effect on serious cardiovascular outcomes
If you were a betting person, you should bet that varenicline likely does increase the risk of cardiovascular events. The point estimate was roughly 6070% but the effect could be as high as a 176% increase or an actual 10% reduction in cardiovascular events [10, 11]. Importantly, baseline cardiovascular risk can vary dramatically. A 30yearold female with no risk factors except smoking may have 0.5% 5year risk or a 0.1% one year risk of a cardiovascular event. If varenincline increased risk by 60%, one extra cardiovascular event would occur for every 1667 patients treated. In patients immediately postMI, whose CVD risk may approach 5% in the first year, varenicline may lead to one extra cardiovascular event for every 34 patients treated (7 of whom would quit smoking). In these patients, the benefits may still outweigh risks but a discussion around potential risks and options would be appropriate. Bottomline, varenicline likely produces an increased risk of cardiovascular events but this risk may be <1/1000 for low risk patients to as much as in 1/34 for the highest risk patients. However, the benefits of smoking cessation are considerable.
Discussion
It appears that medical authors feel the need to make black and white conclusions when their data almost never allows for such dichotomous statements. This is particularly true when comparing results to similar studies with largely overlapping CIs. Virtually all of the conclusion confusion discussed in this paper can be linked to slavish adherence to an arbitrary threshold for statistical significance. Even if the threshold is reasonable, it still cannot be used to make dichotomous conclusions.
Although we have selected three examples here, these are certainly not the only ones. In another example we considered, the authors of two metaanalyses of primary prevention with aspirin report the exact same point estimate and confidence interval 0.94 (0.881.00) but had differing conclusions [12, 13]. We tried to select a small but representative group of examples that would be familiar to most readers.
We are not the first authors to write about the misinterpretation of CIs and statistical significance. About 60 years ago, RA Fischer introduced the pvalue for hypothesis and significance testing [14]. Although 0.05 was suggested as a reasonable indicator for significance, he did assert the interpretation was open [14]. Over 30 years ago, a number of articles were published encouraging medical researchers to report their results with CIs [15–18]. CIs provide an estimation reflecting the potential range of effect rather than simply stating if results are statistically significant or not [15–17]. Unfortunately, this goal fell short as CIs are frequently used to define whether a result is or is not statistically significant. In the 60 plus year history, articles on application of statistical reporting continue to encourage authors to present their findings [17, 19, 20], allow readers to interpret results [14, 17, 19, 20] and not use CIs strictly for reporting statistical significance [17, 20].
We encourage authors to avoid statements like “X has no effect on mortality” as they are likely to be both untrue and misleading. This is especially true as results get “close” to being statistically significant. Results should speak for themselves. For that to happen, readers (clinicians and science reporters) need to understand the language of statistics and approach authors’ conclusions with a critical eye. We are not trying to say that the reader should not review the abstract but when authors’ conclusions differ from others, readers must examine and compare the actual results. In fact, all but one of the metaanalyses provided point estimates and CIs in the abstracts. This facilitates quick comparisons to other studies reported to be “completely different,” and to determine if the CIs demonstrate clinically important differences. The problem lies in the authors’ conclusions, which often have little to do with their results but rather what they want the results to show. We encourage journal editors to challenge authors’ conclusions, particularly when they argue they have found something unique or different than other researchers but the difference is based solely on tiny variations in CIs or pvalue (statistically significant or not).
We are not suggesting the elimination of statistical testing or statistical significance, but rather that all people (authors, publishers, regulators etc.) who write about medical interventions use common sense and good judgment when presenting results that differ from others and not be so beholden to the “magical” statistical significance level of 0.05. We urge them to consider the degree to which the results of the “differing” study overlap with their own, the true difference in the point estimates and range of possible effects, where the preponderance of the effect lies and how clinicians might apply the evidence.
It appears that readers of the papers discussed here would be better served by reviewing the actual results than reading the authors’ conclusions. To do that, clinicians need to be able to interpret the meaning of CIs and statistical significance.
Summary
Dogmatic adherence to statistical significance thresholds can lead authors to write dichotomized absolute conclusions while ignoring the broader interpretations of very consistent findings. These opposing conclusions are false disagreements that create unnecessary clinical uncertainty. Authors are encouraged to report data more pragmatically. Readers and clinicians are encouraged to compare the actual data and precision of the results rather than rely on the conclusions of the authors.
Authors’ information
GMA is general practitioner and academic physician with focus in evidencebased medicine and knowledge translation. JM is doctor of pharmacy and an academic with a focus on evidencebased medicine and knowledge translation. BV is biostatistician and has written on statistical methodology and interpretation.
Abbreviations
 CI:

Confidence intervals
 RCT:

Randomized controlled trial.
Declarations
Acknowledgments
We would like the acknowledge Lynda Cranston, a medical writer, who reviewed a nearfinal draft of the article for grammatical errors and typos.
Authors’ Affiliations
References
 Cowles M, Davis C: On the origins of the.05 level of statistical significance. Am Psychol. 1982, 37: 553558.View Article
 Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC: Effect of different antilipidemic agents and diets on mortality: A Systematic Review. Arch Intern Med. 2005, 165: 725730. 10.1001/archinte.165.7.725.View ArticlePubMed
 Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK: Primary prevention of cardiovascular diseases with statin therapy: a metaanalysis of randomized controlled trials. Arch Intern Med. 2006, 166: 23072313. 10.1001/archinte.166.21.2307.View ArticlePubMed
 Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D: Primary prevention of cardiovascular mortality and events with statin treatments: a network metaanalysis involving more than 65,000 patients. J Am Coll Cardiol. 2008, 52: 17691781. 10.1016/j.jacc.2008.08.039.View ArticlePubMed
 Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, et al: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: metaanalysis of randomised controlled trials. BMJ. 2009, 338: b237610.1136/bmj.b2376.PubMed CentralView ArticlePubMed
 Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I, et al: Statins and allcause mortality in highrisk primary prevention: a metaanalysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010, 170: 10241031. 10.1001/archinternmed.2010.182.View ArticlePubMed
 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361: 11391151. 10.1056/NEJMoa0905561.View ArticlePubMed
 Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365: 981992. 10.1056/NEJMoa1107039.View ArticlePubMed
 Hughes S: ARISTOTLE: A major win for apixaban in AF. 2011, Heartwire, http://www.medscape.com/viewarticle/748682 (accessed November 5, 2013)
 Singh S, Loke YK, Spangler JG, Furberg CD: Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and metaanalysis. CMAJ. 2011, 183: 13591366. 10.1503/cmaj.110218.PubMed CentralView ArticlePubMed
 Prochaska JJ, Hilton JF: Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and metaanalysis. BMJ. 2012, 344: e285610.1136/bmj.e2856.PubMed CentralView ArticlePubMed
 Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK: Effect of aspirin on vascular and nonvascular outcomes: metaanalysis of randomized controlled trials. Arch Intern Med. 2012, 172: 209216. 10.1001/archinternmed.2011.628.View ArticlePubMed
 Raju N, SobierajTeague M, Hirsh J, O’Donnell M, Eikelboom J: Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011, 124: 621629. 10.1016/j.amjmed.2011.01.018.View ArticlePubMed
 Sterne JA, Davey Smith G: Sifting the evidencewhat’s wrong with significance tests?. BMJ. 2001, 322: 226231. 10.1136/bmj.322.7280.226.PubMed CentralView ArticlePubMed
 Rothman KJ: A show of confidence. N Engl J Med. 1978, 299: 13621363. 10.1056/NEJM197812142992410.View ArticlePubMed
 Gardner MJ, Altman DG: Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed). 1986, 292: 746750. 10.1136/bmj.292.6522.746.View Article
 Poole C: Beyond the confidence interval. Am J Public Health. 1987, 77: 195199. 10.2105/AJPH.77.2.195.PubMed CentralView ArticlePubMed
 Bulpitt CJ: Confidence intervals. Lancet. 1987, 329 (8531): 494497. 10.1016/S01406736(87)921003.View Article
 Cooper RJ, Wears RL, Schriger DL: Reporting research results: recommendations for improving communication. Ann Emerg Med. 2003, 41: 561564. 10.1067/mem.2003.135.View ArticlePubMed
 Cummings P, Koepsell TD: P values vs estimates of association with confidence intervals. Arch Pediatr Adolesc Med. 2010, 164: 193196. 10.1001/archpediatrics.2009.266.PubMed
 The prepublication history for this paper can be accessed here:http://www.biomedcentral.com/14712288/13/134/prepub
Prepublication history
Copyright
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.